Amantadine: reappraisal of the timeless diamond—target updates and novel therapeutic potentials

Wojciech Danysz, Andrzej Dekundy, Astrid Scheschonka, Peter Riederer*

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

26 Downloads (Pure)

Abstract

The aim of the current review was to provide a new, in-depth insight into possible pharmacological targets of amantadine to pave the way to extending its therapeutic use to further indications beyond Parkinson’s disease symptoms and viral infections. Considering amantadine’s affinities in vitro and the expected concentration at targets at therapeutic doses in humans, the following primary targets seem to be most plausible: aromatic amino acids decarboxylase, glial-cell derived neurotrophic factor, sigma-1 receptors, phosphodiesterases, and nicotinic receptors. Further three targets could play a role to a lesser extent: NMDA receptors, 5-HT3 receptors, and potassium channels. Based on published clinical studies, traumatic brain injury, fatigue [e.g., in multiple sclerosis (MS)], and chorea in Huntington’s disease should be regarded potential, encouraging indications. Preclinical investigations suggest amantadine’s therapeutic potential in several further indications such as: depression, recovery after spinal cord injury, neuroprotection in MS, and cutaneous pain. Query in the database http://www.clinicaltrials.gov reveals research interest in several further indications: cancer, autism, cocaine abuse, MS, diabetes, attention deficit-hyperactivity disorder, obesity, and schizophrenia.

Original languageEnglish
JournalJournal of Neural Transmission
Volume128
Issue number2
Pages (from-to)127–169
ISSN0300-9564
DOIs
Publication statusPublished - 23. Feb 2021

Fingerprint Dive into the research topics of 'Amantadine: reappraisal of the timeless diamond—target updates and novel therapeutic potentials'. Together they form a unique fingerprint.

Cite this